SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 10, 2026 in ADMA BIOLOGICS, INC. Lawsuit

ADMA Biologics co-founder Jerrold V. Grossman allegedly signed annual reports that concealed channel stuffing and failed to disclose a related-party distributor operating out of ADMA’s own headquarters. The allegations raise material accounting/compliance concerns and could prompt regulatory scrutiny or financial restatements. Likely negative for ADMA’s credibility and near-term investor sentiment, with a potential 1–3% stock impact depending on follow-up filings.

Analysis

ADMA Biologics co-founder Jerrold V. Grossman allegedly signed annual reports that concealed channel stuffing and failed to disclose a related-party distributor operating out of ADMA’s own headquarters. The allegations raise material accounting/compliance concerns and could prompt regulatory scrutiny or financial restatements. Likely negative for ADMA’s credibility and near-term investor sentiment, with a potential 1–3% stock impact depending on follow-up filings.